EXCITING DEVELOPMENTS

There is new information about a medication being studied focusing on the positive outcomes in patients with chronic kidney disease. AstraZeneca’s Farxiga could be closer to securing approval as a treatment for chronic kidney disease (CKD). 

Dr. Dylan Steer, CEO Balboa Nephrology Medical Group commented; “Several medications in this new class of diabetes medications – “SGLT2 inhibitors” – are now showing great outcomes in several large clinical trials of patients with diabetic chronic kidney disease in terms of slowing down loss of kidney function.  In addition to certain blood pressure medications, such as ACEi and ARB, these new diabetes medications may help delay progression of kidney disease and improve the outcomes that matter most to patients.  We don’t yet know if all of the medications in the SGLT2 inhibitor class of medications have the same effect, but several of them do.  These are exciting developments in the care of patients with diabetic chronic kidney disease.”

Read the article in its entirety here: https://bit.ly/2XWPEGK

CREDIT: BioSpace